by In2Pharma | Feb 26, 2024 | News
Belgium Hospitals must, according to the Royal Decree of 13 September 2023, issue a tender for biological and biosimilar medicines within nine months after a first biosimilar pharmaceutical speciality, authorized in accordance with the law of March 25, 1964 on...
by In2Pharma | Feb 12, 2024 | News
The Netherlands Koag Kag/Keuringsraad has published the data for their basic training on the codes for promotion towards general public regarding medicinal products, medical devices and health products. This training takes place in Breukelen, The Netherlands, at...
by In2Pharma | Feb 11, 2024 | News
Luxembourg On January 17th, EMA published the newest version (v28) of QRD Appendix V. In this version, the contact details for reporting adverse drug reactions in Luxemburg has been changed, to include the German version of the address. Luxembourg/Luxemburg [French]...
by In2Pharma | Feb 10, 2024 | News
The Netherlands Via the MEB website, a planning tool is already available to reserve a timeslot for requesting assessment procedures for decentralized procedures. The planning tool helps the MEB to properly plan the required capacity. This tool has now been expanded...
by In2Pharma | Dec 29, 2023 | News
Belgium Since 03 December 2023, a new royal decree has been published regarding the reporting of adverse reactions related to the use of food supplements. This Royal Decree defines the legal framework for Nutrivigilance, but not its mode of operation in...
